脑部放疗，上午比下午敏感许多！
; i& B2 o) B9 Z U& L h+ @3 V3 D" ~
0 W n; D7 j- ^4 @) e
Cancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.
' A# [1 a1 @! t8 P# cGamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?
: m' h1 R' c4 a, m' e2 G& mRahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.
" |% T6 C0 G. K; A9 c% m1 WSourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.
( K! F: {6 y3 F* J/ X& ~( i9 Y; z2 [0 t8 _/ g7 J3 v" K
Abstract9 z7 ^* F8 T' E- F# ]+ _- v
BACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.
* E7 H) k# V3 A3 ?( r ]: y& A; @
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.) w3 |8 U& j9 X" O# B
5 s2 T$ M- ~6 ~, U- [
RESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).
" ]( N; m+ [6 S, r8 z" c' B* ~# x: B4 b i
CONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.5 _" g/ y& S7 z ^3 }4 a' Z) {
: Y6 C5 N/ O8 z% d3 I7 W" R
|
求助，请大家帮忙出出主意，奥西+280
病人是我妈妈，43年8月的，81周岁。
19年10月28日确诊，肺腺癌晚期，右上肺肺癌并双
肺癌晚期三代靶向药耐药后，我为自己
讲述者：薰衣草整理者：pear
2022年6月我确诊肺癌晚期，虽有EGFR突变，但我却对靶向药
求助：肺腺癌3年，脑转脑膜转骨转，E
肺腺癌3年，脑转脑膜转、骨转，E19+797S突变，免疫阴性，阿美29个月，期间放疗2次，后
妈妈与脑膜转奋战4年多，如今也成功
作者：李妮妮
2020年12月1号，妈妈在确诊晚期肺癌4年零10月，经历了化疗、一代靶向易
依沃西用药后，该怎么办？
依沃西用药后，该怎么办？
我爸爸于2024年7月确诊肺鳞癌，整个治疗过程如附件里表格
8 h8 m b4 _, F5 z4 H0 m+ g# b
显身卡
